Crestor (Rosuvastatin) Cost in New York: 2026 Prices, Insurance, and Savings

Rosuvastatin is the generic name for the branded statin Crestor (AstraZeneca), an oral HMG-CoA reductase inhibitor taken once daily, usually as a 5 mg to 40 mg tablet. It is FDA-approved for lowering LDL cholesterol, reducing cardiovascular risk in patients with elevated risk factors, and slowing progression of atherosclerosis. This article does not cover compounded rosuvastatin liquids or capsules as a substitute for the approved tablet without a documented clinical reason, discussed further below.

The direct answer: in New York, as in most states, the cost story for rosuvastatin is not really a geography story. Generic rosuvastatin is a low-cost, widely stocked medication nationally, and the price differences a patient will actually encounter in New York come almost entirely from three things: whether they have insurance, whether that insurer requires prior authorization (notably New York Medicaid), and which discount tool or pharmacy network they use. Brand Crestor, by contrast, carries a much higher list price and is rarely the right default once a generic exists. Below, we separate what is stable and verifiable from what changes month to month and needs to be checked at the point of purchase.

Brand versus generic: the gap that actually drives cost

Generic rosuvastatin has been FDA-approved and available since 2016, following patent expiration on brand Crestor. Once a generic AB-rated equivalent exists, it is typically far cheaper than the brand and is what most insurance plans and pharmacies dispense by default unless a prescriber specifically requests "dispense as written" for the brand.

Brand-name Crestor carries a list price that is dramatically higher than generic rosuvastatin, commonly cited in the range of several hundred dollars per month before any discount or insurance adjustment. Generic rosuvastatin cash prices, by contrast, are commonly reported in the low double digits or less per month through discount programs. These are national patterns, not New York-specific figures, and exact numbers move with contract pricing, so any dollar figure you see quoted (including elsewhere on this page) should be treated as approximate and confirmed at the pharmacy counter or through a current price-checking tool before you rely on it for a budgeting decision.

Does New York Medicaid cover rosuvastatin?

New York Medicaid covers rosuvastatin, but under most managed care plans it sits on a non-preferred tier, which means prior authorization is generally required before the state's pharmacy benefit will pay for it. Atorvastatin, an older generic statin, is typically the preferred first-line option on New York's Medicaid formulary and usually does not require this extra step. A prescriber seeking rosuvastatin for a Medicaid patient generally needs to document a clinical reason, such as atorvastatin intolerance or failure to reach LDL targets on maximum atorvastatin dosing.

The exact turnaround time for a prior authorization request, and the copay a Medicaid enrollee pays once approved, depend on the specific managed care organization (for example Fidelis Care, Healthfirst, MetroPlus, or Molina) and can change from year to year. Patients and prescribers should confirm current requirements directly through the New York State Medicaid pharmacy program rather than relying on a fixed number, since preferred drug lists are revised periodically.

Commercial insurance, Medicare Part D, and the ACA marketplace

Most commercial insurance formularies in New York place generic rosuvastatin on a low, preferred-generic tier, and brand Crestor (when covered at all) on a higher, non-preferred brand tier with a meaningfully larger copay. Exact copay amounts vary by employer, plan design, and pharmacy benefit manager, and should be confirmed through the plan's own formulary tool rather than assumed from a general estimate.

Medicare Part D plans in New York very commonly place generic rosuvastatin on a low-cost or $0 preferred generic tier, and the Inflation Reduction Act's Part D out-of-pocket cap, phased in through CMS's Medicare drug pricing provisions, affects the ceiling on total annual drug spending for enrollees taking multiple medications, though the practical effect for a patient taking only rosuvastatin is usually smaller because their baseline spending is already low. ACA marketplace plans sold through New York State of Health are required to cover at least one statin as an essential health benefit, and generic rosuvastatin is commonly included, though tier placement differs by carrier and should be checked for the specific plan year.

Compounded rosuvastatin: a narrow, specific-use option

Compounded rosuvastatin can be prepared by licensed 503A compounding pharmacies in New York, which operate under oversight from the New York State Board of Pharmacy and under the federal compounding framework for licensed compounders. This is not the same product as FDA-approved rosuvastatin tablets: compounded preparations are not FDA-approved, are not AB-rated to the commercial product, and are almost never covered by insurance, including Medicaid.

Compounding exists for patients with a specific clinical need that a commercial tablet cannot meet, such as an inability to swallow tablets, a documented allergy to an inactive ingredient, or a need for a strength that is not commercially manufactured. It is not intended as a general cost-saving substitute for the approved product, and federal rules restrict 503A compounding to patient-specific prescriptions rather than bulk or "office stock" distribution. Anyone considering a compounded formulation should confirm the pharmacy's current New York license and ask directly whether the formulation has been tested for stability and potency, since compounded products do not go through the same premarket review as the approved tablet.

Telehealth prescribing in New York

New York permits telehealth prescribing of rosuvastatin, which is not a controlled substance. A clinician licensed in New York can conduct a synchronous video or audio visit, review a recent lipid panel, and send an electronic prescription to any New York pharmacy. This is most useful for patients in parts of the state with limited access to a cardiologist or lipid specialist, such as the North Country or Southern Tier.

The standard of care for a telehealth statin prescription is the same as for an in-person visit: a recent lipid panel, baseline liver function assessment where clinically indicated, a discussion of potential side effects including muscle symptoms, and a dose selected according to the patient's cardiovascular risk profile rather than a default. Telehealth does not lower this bar; it changes the visit format, not the clinical standard.

What the trial evidence actually supports, and its limits

Rosuvastatin's FDA-approved indications, current dosing range, and labeled warnings are described in its FDA prescribing information, which is the primary source for what the drug is approved to do and at what doses. Beyond the label, two randomized trials are frequently cited in discussions of rosuvastatin: one that compared rosuvastatin against other statins on LDL-lowering potency across doses, and one that tested rosuvastatin in patients with elevated inflammatory markers but not classically elevated LDL. Both are widely referenced in the cardiology literature. Because specific effect-size numbers (percentage LDL reduction, percentage event reduction) are easy to misquote or misattribute, this draft does not restate precise figures from those trials without verifying them against the original publication; anyone using this page to counsel a specific patient should pull the primary trial report rather than relying on secondhand numbers.

Similarly, claims that statin non-adherence increases cardiovascular event risk by a specific percentage are plausible and consistent with general adherence literature, but the exact figure needs to be checked against the original study before being used as a quoted statistic. The safest general statement supportable here is that cost-related non-adherence is a recognized driver of poor statin outcomes, without attaching an unverified number to it.

What is established, what is plausible, and what is not established

Established: Generic rosuvastatin is FDA-approved, widely available, and substantially cheaper than brand Crestor. New York Medicaid covers rosuvastatin but generally requires prior authorization because it sits on a non-preferred formulary tier relative to atorvastatin. Compounded rosuvastatin is legal in New York only through licensed 503A pharmacies filling patient-specific prescriptions, and is not FDA-approved or typically insurance-covered. Telehealth prescribing of rosuvastatin is permitted in New York.

Plausible but not confirmed in this draft: Specific dollar figures for cash price by pharmacy chain, borough, or region; exact prior authorization turnaround times; and exact percentage effect sizes from named clinical trials. These numbers exist in the literature and in pharmacy pricing data, but they change often enough, and were unverifiable against a checked primary source at the time of writing, that they should not be treated as fixed facts.

Not established here: Any claim that compounded rosuvastatin is bioequivalent to the commercial tablet, or that a specific savings card, discount program, or pharmacy will offer the lowest price for every patient. Savings programs and pharmacy pricing are volatile and patient-situation-specific; a program that is cheapest for a commercially insured patient may not apply at all to a Medicare or Medicaid patient.

Verification checklist: stable facts versus facts you must re-check

Consult this information before discussing rosuvastatin pricing or insurance coverage with a patient. Information in the left column describes stable rosuvastatin formulations and dosing that rarely change. Information in the right column covers costs and plan policies that fluctuate and should be verified on the day you advise the patient.

Stable (verify occasionally, changes slowly)

• Rosuvastatin's FDA-approved indications and dosing range: check the current FDA label.
• Generic rosuvastatin's approval status: confirm through FDA's Drugs@FDA database.
• That New York Medicaid can require prior authorization for non-preferred statins: confirmed through NY Medicaid's pharmacy program page.
• That 503A compounding is legal only for patient-specific prescriptions under federal rule.
• That New York licenses and oversees compounding pharmacies through its Board of Pharmacy: confirmed through the NY Board of Pharmacy.
• That telehealth prescribing of non-controlled substances is permitted in New York.

Volatile (re-verify at time of use, ideally with a date stamp)

• Cash price of generic rosuvastatin at a specific pharmacy or chain, including warehouse club and mail-order pricing.
• List price of brand Crestor.
• Whether a given Medicaid managed care plan (Fidelis, Healthfirst, MetroPlus, Molina, etc.) currently requires prior authorization for rosuvastatin, and the current turnaround time.
• Formulary tier and copay for rosuvastatin or Crestor under a specific commercial, Part D, or marketplace plan.
• Eligibility rules and benefit amount for New York's EPIC program for seniors.
• Whether a manufacturer savings card, discount card, or mail-order service is currently offering a given price, since these programs change terms without notice.
• Current pricing or existence of any named compounding pharmacy's rosuvastatin formulation.

When a rosuvastatin price or coverage detail cannot be verified using the reliable sources listed above or by checking current pharmacy and insurance databases with today's date, present it to the patient as an estimate rather than a definitive fact.

Comparing rosuvastatin to other generic statins

Rosuvastatin is not the cheapest generic statin on the market; atorvastatin, simvastatin, and pravastatin are also low-cost generics and are frequently the preferred first-line option on formularies, including New York Medicaid's. The clinical literature on comparative LDL-lowering potency across these statins is well established in general direction (rosuvastatin and atorvastatin are both considered higher-potency options relative to simvastatin and pravastatin at typical doses), but exact percentage comparisons should be pulled from the primary trial literature rather than repeated as a fixed statistic. National cholesterol management guidance classifies rosuvastatin 20 to 40 mg, alongside atorvastatin 40 to 80 mg, as high-intensity statin therapy for patients meeting guideline-based risk criteria; for many patients, either drug at an appropriate dose can achieve the same LDL target, and the choice between them often comes down to tolerability, drug interactions, and out-of-pocket cost rather than a meaningful efficacy gap.

Practical steps for New York residents filling this prescription

Confirm your insurance formulary placement for rosuvastatin before your prescriber sends it to a pharmacy, and ask specifically whether prior authorization is required. If you are on New York Medicaid, expect that rosuvastatin will need a documented clinical justification unless your plan's rules have changed. If you are uninsured, ask a pharmacy for its current cash price for the generic rather than assuming a "retail" price is fixed, and compare at least two or three pharmacies or a discount tool before filling. If you are 65 or older and income-eligible, ask whether New York's EPIC program can supplement your Part D coverage. If cost remains a genuine barrier after checking these options, that is a conversation to have directly with your prescriber, since a lower-cost statin alternative or a patient assistance program may be a better fit than switching to an unproven compounded formulation.

When to seek urgent care rather than troubleshoot cost: unexplained muscle pain or weakness, dark urine, or signs of liver problems (yellowing skin or eyes, persistent nausea) while taking rosuvastatin warrant prompt medical evaluation rather than waiting for a routine follow-up, regardless of insurance status.